GB8727055D0 - Galenical retard form - Google Patents

Galenical retard form

Info

Publication number
GB8727055D0
GB8727055D0 GB878727055A GB8727055A GB8727055D0 GB 8727055 D0 GB8727055 D0 GB 8727055D0 GB 878727055 A GB878727055 A GB 878727055A GB 8727055 A GB8727055 A GB 8727055A GB 8727055 D0 GB8727055 D0 GB 8727055D0
Authority
GB
United Kingdom
Prior art keywords
galenical
retard form
retard
galenical retard
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB878727055A
Other versions
GB2196851A (en
GB2196851B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of GB8727055D0 publication Critical patent/GB8727055D0/en
Publication of GB2196851A publication Critical patent/GB2196851A/en
Application granted granted Critical
Publication of GB2196851B publication Critical patent/GB2196851B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GB8727055A 1984-06-14 1987-11-19 Novel galenical retard form Expired GB2196851B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3422083 1984-06-14
DE3442566 1984-11-22

Publications (3)

Publication Number Publication Date
GB8727055D0 true GB8727055D0 (en) 1987-12-23
GB2196851A GB2196851A (en) 1988-05-11
GB2196851B GB2196851B (en) 1989-06-07

Family

ID=25822108

Family Applications (3)

Application Number Title Priority Date Filing Date
GB8514855A Expired GB2160100B (en) 1984-06-14 1985-06-12 Novel galenical retard form
GB8727056A Expired GB2196852B (en) 1984-06-14 1987-11-19 Novel galenical retard form
GB8727055A Expired GB2196851B (en) 1984-06-14 1987-11-19 Novel galenical retard form

Family Applications Before (2)

Application Number Title Priority Date Filing Date
GB8514855A Expired GB2160100B (en) 1984-06-14 1985-06-12 Novel galenical retard form
GB8727056A Expired GB2196852B (en) 1984-06-14 1987-11-19 Novel galenical retard form

Country Status (21)

Country Link
AT (1) AT391806B (en)
AU (2) AU587190B2 (en)
BE (1) BE902626A (en)
CA (1) CA1264441A (en)
CY (1) CY1635A (en)
DE (1) DE3520184C2 (en)
DK (1) DK167649B1 (en)
ES (1) ES8702141A1 (en)
FR (1) FR2565822B1 (en)
GB (3) GB2160100B (en)
GR (1) GR851430B (en)
HK (1) HK25192A (en)
HU (1) HU198844B (en)
IE (1) IE58834B1 (en)
IL (1) IL75490A0 (en)
IT (1) IT1200080B (en)
LU (1) LU85946A1 (en)
NL (1) NL194389C (en)
NZ (1) NZ212390A (en)
PT (1) PT80635B (en)
SE (1) SE504583C2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187751B (en) * 1985-10-15 1987-12-23 Eurand Spa PROCEDURE FOR THE PREPARATION OF SOLID FORMULATIONS OF NIFEDIPINE WITH HIGH BIO AVAILABILITY AND WITH PROLONGED EFFECT AND FORMULATIONS SO OBTAINED
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
EP0406315B1 (en) * 1988-03-24 1992-11-11 Bukh Meditec A/S Controlled release composition
GR1000270B (en) * 1988-09-30 1992-05-12 Alza Corp Dose for cardiovascular troubles therapy
DK469989D0 (en) * 1989-09-22 1989-09-22 Bukh Meditec PHARMACEUTICAL PREPARATION
MX9300110A (en) * 1992-01-13 1994-07-29 Gerhard Gergely PHARMACEUTICAL PREPARATION IN THE FORM OF AN EFFERVESCENCE OR DISINTEGRATION TABLET OR OF AN INSTANT-TYPE GRANULATE AND PROCEDURE FOR ITS PREPARATION.
DE4201179A1 (en) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Granulates or pellets comprising dispersion of active agent in hydrophilic macromolecules - are e.g. for treatment of depression, hypertension, rheumatism, etc.
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
US6093420A (en) 1996-07-08 2000-07-25 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
DE19710009A1 (en) * 1997-03-12 1998-09-24 Knoll Ag Multi-phase preparation forms containing active ingredients
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
WO2000076480A2 (en) * 1999-06-11 2000-12-21 Eli Lilly And Company Pharmaceutical materials and methods for their preparation and use
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
ATE324909T1 (en) * 1999-08-04 2006-06-15 Astellas Pharma Inc STABLE MEDICAL COMPOSITIONS FOR ORAL ADMINISTRATION USING IRON OXIDES
JP3893058B2 (en) 1999-09-30 2007-03-14 ペンウェスト ファーマシューティカルズ カンパニー Sustained release matrix system for highly soluble drugs
EP1368006B1 (en) * 2001-02-13 2006-05-03 AstraZeneca AB Novel modified released formulation
US7135436B2 (en) 2003-05-05 2006-11-14 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
EP1690528A1 (en) 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Process for the preparation of dosage forms comprising a solid dispersion of a microcrystalline active agent
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
CA2670749A1 (en) 2006-12-05 2008-06-12 Landec Corporation Drug delivery
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
CN102271661A (en) * 2008-08-20 2011-12-07 德克萨斯州立大学董事会 Hot-melt extrusion of modified release multi-particulates

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617362A1 (en) * 1967-11-17 1971-03-25 Beiersdorf Ag Process for the production of medicaments with delayed release of active substances in the form of capsules
DE2400819C2 (en) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Process for the production of solid preparations of poorly soluble active pharmaceutical ingredients in extremely fine distribution
DE2546577B2 (en) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Solid substances made from polyvinylpyrrolidone and ergot alkaloids
GB1504553A (en) * 1975-11-17 1978-03-22 Sandoz Ltd Tablet formulations
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
DK149855C (en) * 1977-06-20 1987-04-21 Sandoz Ag METHOD OF ANALOGY FOR THE PREPARATION OF 1,4-DIHYDROPYRIDINE DERIVATIVES
CH639659A5 (en) * 1978-12-18 1983-11-30 Sandoz Ag NEW 1,4-DIHYDROPYRIDINE DERIVATIVES, THEIR PRODUCTION AND USE.
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
DK154607C (en) * 1978-12-21 1989-06-05 Sandoz Ag PROCEDURE FOR PREPARING A PHARMACEUTICAL FORM FOR ORAL ADMINISTRATION OF ERGOTAL KALOIDS
DE2904310A1 (en) * 1979-02-05 1980-08-07 Boehringer Mannheim Gmbh MOLDINGS WITH RETARDED ACTIVE SUBSTANCE RELEASE AND METHOD FOR THE PRODUCTION THEREOF
JPS56115726A (en) * 1980-02-20 1981-09-11 Kaken Pharmaceut Co Ltd Pharmaceutical containing nifedipine
DE3033919A1 (en) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen SOLID PHARMACEUTICAL PREPARATIONS CONTAINING NIFEDIPINE AND METHOD FOR THE PRODUCTION THEREOF
US4442112A (en) * 1981-09-02 1984-04-10 Sandoz Ltd. Dihydropyridine derivatives useful in treating vascular headaches
EP0078430B2 (en) * 1981-10-29 1993-02-10 Bayer Ag Process for preparing solid fast-releasing drug formulations of dihydropyridines
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
DE3318649A1 (en) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen TWO-PHASE FORMULATION

Also Published As

Publication number Publication date
GR851430B (en) 1985-11-25
IT8548210A0 (en) 1985-06-13
AT391806B (en) 1990-12-10
IE58834B1 (en) 1993-11-17
GB2196851A (en) 1988-05-11
DK264785D0 (en) 1985-06-12
GB2196852B (en) 1989-05-17
CY1635A (en) 1992-11-06
ES8702141A1 (en) 1987-01-01
AU4454389A (en) 1990-03-22
CA1264441A (en) 1990-01-16
GB2196851B (en) 1989-06-07
HU198844B (en) 1989-12-28
HK25192A (en) 1992-04-10
SE8502950D0 (en) 1985-06-13
FR2565822B1 (en) 1989-02-17
ATA174885A (en) 1990-06-15
DE3520184C2 (en) 1997-03-13
GB2196852A (en) 1988-05-11
IE851460L (en) 1985-12-14
LU85946A1 (en) 1986-01-24
NL194389B (en) 2001-11-01
IL75490A0 (en) 1985-10-31
DK167649B1 (en) 1993-12-06
ES544075A0 (en) 1987-01-01
SE8502950L (en) 1985-12-15
SE504583C2 (en) 1997-03-10
IT1200080B (en) 1989-01-05
PT80635A (en) 1985-07-01
GB2160100A (en) 1985-12-18
GB8514855D0 (en) 1985-07-17
AU4348685A (en) 1985-12-19
BE902626A (en) 1985-12-10
NZ212390A (en) 1992-02-25
NL8501578A (en) 1986-01-02
DE3520184A1 (en) 1985-12-19
AU587190B2 (en) 1989-08-10
GB8727056D0 (en) 1987-12-23
DK264785A (en) 1985-12-15
HUT40918A (en) 1987-03-30
GB2160100B (en) 1989-06-01
FR2565822A1 (en) 1985-12-20
NL194389C (en) 2002-03-04
PT80635B (en) 1987-10-20

Similar Documents

Publication Publication Date Title
GB2196852B (en) Novel galenical retard form
GB2163150B (en) 3-aminopropoxyaryl derivatives
GB2152033B (en) Sulfonamido-benzamide derivatives
EP0163324A3 (en) Aminoalkylphenoxy derivatives
GB2155925B (en) Pyrimidylpiperazine derivatives
GB2164644B (en) Benzonorbornene derivatives
GB8519921D0 (en) Closures
DE3565267D1 (en) 9a-aza-9a-homoerythromycin derivatives
GB8519922D0 (en) Closures
GB2159814B (en) Iminothiazolidine derivatives
DE3571335D1 (en) Stop
GB2165845B (en) Dioxinopyridine derivatives
GB2165247B (en) Azabicycloheptene derivatives
GB2162178B (en) 4-cyano-3-oxo-hexahydro-isoquinoline derivatives
EP0174271A3 (en) Anthraceme derivatives
GB8419223D0 (en) Sulphamoylguanidine derivatives
GB2158066B (en) Apovincaminol derivatives
GB8422379D0 (en) Derivatives
SG15492G (en) Novel galenical retard form
ZA854520B (en) Novel galenic retard form
GB2169290B (en) Pyrone -3- carboxamide derivatives
GB8401010D0 (en) Thioketene derivatives
GB2165243B (en) 17-sulphonamido yohimbane derivatives
GR80391B (en) Simple form
GR82486B (en) Safe

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)
PE20 Patent expired after termination of 20 years

Effective date: 20050611